Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:23 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 531210 | NSE: COLINZ

Colinz Laboratories Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹20.50Overvalued by 55.43%vs CMP ₹46.00

P/E (11.8) × ROE (5.4%) × BV (₹39.20) × DY (2.00%)

₹40.78Overvalued by 11.35%vs CMP ₹46.00
MoS: -12.8% (Negative)Confidence: 48/100 (Moderate)Models: 2 Under, 2 Fair, 5 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹24.9023%Over (-45.9%)
Graham NumberEarnings₹41.5816%Fair (-9.6%)
Earnings PowerEarnings₹26.9814%Over (-41.3%)
DCFCash Flow₹90.2711%Under (+96.2%)
Net Asset ValueAssets₹78.497%Under (+70.6%)
EV/EBITDAEnterprise₹44.019%Fair (-4.3%)
Earnings YieldEarnings₹19.607%Over (-57.4%)
ROCE CapitalReturns₹30.777%Over (-33.1%)
Revenue MultipleRevenue₹25.945%Over (-43.6%)
Consensus (9 models)₹40.78100%Overvalued
Key Drivers: Wide model spread (₹20–₹90) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 21.5%

*Investments are subject to market risks

Investment Snapshot

46
Colinz Laboratories Ltd scores 46/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health62/100 · Moderate
ROCE 6.7% WeakROE 5.4% WeakD/E 0.13 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
Promoter holding at 66.0% Stable
Earnings Quality50/100 · Moderate
OPM stable around 8% Steady
Quarterly Momentum25/100 · Weak
Revenue (4Q): -13% YoY DecliningProfit (4Q): 0% YoY Declining
Industry Rank35/100 · Weak
P/E 11.8 vs industry 53.8 Cheaper than peersROCE 6.7% vs industry 16.4% Below peersROE 5.4% vs industry 15.2% Below peers3Y sales CAGR: -2% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:23 am

Market Cap 5.79 Cr.
Current Price 46.0
Intrinsic Value₹40.78
High / Low 87.9/36.1
Stock P/E11.8
Book Value 39.2
Dividend Yield0.00 %
ROCE6.72 %
ROE5.43 %
Face Value 10.0
PEG Ratio0.55

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Colinz Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Colinz Laboratories Ltd 5.79 Cr. 46.0 87.9/36.111.8 39.20.00 %6.72 %5.43 % 10.0
Gennex Laboratories Ltd 208 Cr. 8.55 17.2/7.0511.9 8.790.00 %13.0 %10.2 % 1.00
Dipna Pharmachem Ltd 24.3 Cr. 9.25 26.3/7.4511.9 24.50.00 %6.64 %2.55 % 10.0
Natco Pharma Ltd 17,945 Cr. 1,002 1,060/66011.5 4830.60 %32.8 %28.0 % 2.00
Checkpoint Trends Ltd 25.0 Cr. 45.8 144/14.712.2 3.600.00 %16.5 %9.17 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Colinz Laboratories Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 1.681.721.901.791.711.631.751.861.471.451.571.391.43
Expenses 1.551.561.741.671.571.511.591.691.401.351.441.311.33
Operating Profit 0.130.160.160.120.140.120.160.170.070.100.130.080.10
OPM % 7.74%9.30%8.42%6.70%8.19%7.36%9.14%9.14%4.76%6.90%8.28%5.76%6.99%
Other Income 0.040.040.040.080.050.110.070.080.080.080.080.160.08
Interest 0.010.010.010.010.010.010.010.010.010.020.010.010.01
Depreciation 0.030.030.030.030.030.030.030.030.030.030.040.040.04
Profit before tax 0.130.160.160.160.150.190.190.210.110.130.160.190.13
Tax % 23.08%18.75%18.75%25.00%26.67%31.58%26.32%23.81%45.45%-23.08%25.00%26.32%30.77%
Net Profit 0.100.130.120.120.110.140.140.160.050.150.120.140.08
EPS in Rs 0.400.520.480.480.440.560.560.640.200.600.480.560.32

Last Updated: February 2, 2026, 1:46 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 2:45 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 7.417.888.108.057.837.597.536.166.977.157.036.535.84
Expenses 7.077.427.657.647.487.247.225.826.386.526.496.045.43
Operating Profit 0.340.460.450.410.350.350.310.340.590.630.540.490.41
OPM % 4.59%5.84%5.56%5.09%4.47%4.61%4.12%5.52%8.46%8.81%7.68%7.50%7.02%
Other Income 0.130.100.100.090.100.120.130.190.170.150.280.300.40
Interest 0.080.120.120.120.080.100.070.090.080.050.040.040.05
Depreciation 0.260.300.280.270.220.220.190.190.200.130.130.130.15
Profit before tax 0.130.140.150.110.150.150.180.250.480.600.650.620.61
Tax % 46.15%35.71%40.00%-27.27%-53.33%26.67%27.78%16.00%29.17%23.33%26.15%20.97%
Net Profit 0.070.100.090.140.230.120.130.210.340.460.490.500.49
EPS in Rs 0.150.220.200.310.500.260.280.460.741.831.951.981.96
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)42.86%-10.00%55.56%64.29%-47.83%8.33%61.54%61.90%35.29%6.52%2.04%
Change in YoY Net Profit Growth (%)0.00%-52.86%65.56%8.73%-112.11%56.16%53.21%0.37%-26.61%-28.77%-4.48%

Colinz Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-2%
5 Years:-3%
3 Years:-2%
TTM:-8%
Compounded Profit Growth
10 Years:17%
5 Years:31%
3 Years:14%
TTM:-6%
Stock Price CAGR
10 Years:11%
5 Years:40%
3 Years:3%
1 Year:-28%
Return on Equity
10 Years:4%
5 Years:5%
3 Years:6%
Last Year:5%

Last Updated: September 5, 2025, 3:01 pm

Balance Sheet

Last Updated: December 10, 2025, 4:05 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 3.543.543.543.543.543.543.543.553.552.522.522.522.52
Reserves 2.782.622.712.983.213.303.293.754.145.626.436.967.36
Borrowings 1.882.531.800.760.420.680.380.990.480.270.570.640.66
Other Liabilities 1.791.971.702.402.421.651.601.811.761.821.841.701.59
Total Liabilities 9.9910.669.759.689.599.178.8110.109.9310.2311.3611.8212.13
Fixed Assets 3.723.162.882.632.412.212.062.031.861.711.581.701.62
CWIP 0.000.000.000.000.000.000.000.000.000.000.000.000.00
Investments 0.320.290.290.410.530.500.360.610.670.661.021.041.21
Other Assets 5.957.216.586.646.656.466.397.467.407.868.769.089.30
Total Assets 9.9910.669.759.689.599.178.8110.109.9310.2311.3611.8212.13

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 0.640.090.580.060.340.120.582.160.470.401.03-1.45
Cash from Investing Activity + 0.000.030.00-0.01-0.11-0.01-0.04-0.16-0.030.010.01-0.23
Cash from Financing Activity + -0.370.45-0.73-0.030.010.020.060.080.090.110.230.24
Net Cash Flow 0.270.57-0.160.020.240.120.602.070.520.521.27-1.45
Free Cash Flow 0.640.090.580.040.340.120.542.000.430.401.03-1.71
CFO/OP 194%26%136%22%106%43%210%659%105%89%224%-253%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-1.54-2.07-1.35-0.35-0.07-0.33-0.07-0.650.110.36-0.03-0.15

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 65.5162.5360.8366.6578.3180.7972.2277.0363.3657.6944.6536.89
Inventory Days 188.53288.96232.18267.25266.31246.80225.13208.33147.59149.17134.31136.22
Days Payable 93.17116.2460.6655.6891.9344.1649.2990.0076.17103.1594.8194.31
Cash Conversion Cycle 160.87235.25232.35278.23252.70283.42248.06195.36134.78103.7184.1578.81
Working Capital Days 89.65110.24100.0471.1972.7289.4579.010.009.9511.23-22.8472.66
ROCE %2.51%3.20%3.23%3.00%3.18%3.40%3.39%4.39%6.80%8.08%7.70%6.72%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 66.00%66.00%66.00%66.00%66.00%66.00%66.00%66.00%66.00%66.00%66.00%66.00%
DIIs 0.12%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public 33.88%34.00%34.00%34.00%34.00%34.00%34.00%33.99%33.99%34.00%33.99%34.00%
No. of Shareholders 2,8112,8252,8732,9152,9292,9803,1163,2023,2163,2383,2723,212

Shareholding Pattern Chart

No. of Shareholders

Colinz Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 1.971.931.820.740.99
Diluted EPS (Rs.) 1.971.931.820.740.99
Cash EPS (Rs.) 2.492.452.331.520.58
Book Value[Excl.RevalReserv]/Share (Rs.) 37.6135.5232.3121.6820.57
Book Value[Incl.RevalReserv]/Share (Rs.) 37.6135.5232.3121.6820.57
Revenue From Operations / Share (Rs.) 25.9127.9128.4019.6717.37
PBDIT / Share (Rs.) 3.153.253.102.130.93
PBIT / Share (Rs.) 2.632.732.591.570.93
PBT / Share (Rs.) 2.462.582.381.350.69
Net Profit / Share (Rs.) 1.971.931.810.950.58
PBDIT Margin (%) 12.1411.6310.9110.855.38
PBIT Margin (%) 10.139.789.117.965.38
PBT Margin (%) 9.489.258.386.883.98
Net Profit Margin (%) 7.606.926.394.863.37
Return on Networth / Equity (%) 5.245.435.614.412.84
Return on Capital Employeed (%) 6.857.497.816.994.41
Return On Assets (%) 4.204.284.473.412.05
Total Debt / Equity (X) 0.060.060.030.060.13
Asset Turnover Ratio (%) 0.560.650.700.690.65
Current Ratio (X) 4.174.004.153.722.82
Quick Ratio (X) 3.813.623.663.262.34
Inventory Turnover Ratio (X) 8.020.560.660.550.37
Interest Coverage Ratio (X) 18.7021.9814.9310.033.83
Interest Coverage Ratio (Post Tax) (X) 12.7114.089.755.493.40
Enterprise Value (Cr.) 13.343.033.363.63-0.99
EV / Net Operating Revenue (X) 2.040.430.460.52-0.16
EV / EBITDA (X) 16.823.704.304.79-3.00
MarketCap / Net Operating Revenue (X) 2.801.351.231.200.43
Price / BV (X) 1.931.061.081.090.36
Price / Net Operating Revenue (X) 2.801.351.231.200.43
EarningsYield 0.020.050.050.040.07

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Colinz Laboratories Ltd. is a Public Limited Listed company incorporated on 06/10/1986 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24200MH1986PLC041128 and registration number is 041128. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 6.53 Cr. and Equity Capital is Rs. 2.52 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsA-101, Pratik Ind.Estate, Mulund-Goregaon Link Road, Mumbai Maharashtra 400078Contact not found
Management
NamePosition Held
Mr. N K MenonWhole Time Director
Mr. A Krishna KumarIndependent Director
Dr. Mani L SNon Executive Director
Mr. Bhavik Ashokkumar ShahIndependent Director
Mr. Baptist Bernard DiasIndependent Director

FAQ

What is the intrinsic value of Colinz Laboratories Ltd and is it undervalued?

As of 20 April 2026, Colinz Laboratories Ltd's intrinsic value is ₹40.78, which is 11.35% lower than the current market price of ₹46.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (5.43 %), book value (₹39.2), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Colinz Laboratories Ltd?

Colinz Laboratories Ltd is trading at ₹46.00 as of 20 April 2026, with a FY2026-2027 high of ₹87.9 and low of ₹36.1. The stock is currently near its 52-week low. Market cap stands at ₹5.79 Cr..

How does Colinz Laboratories Ltd's P/E ratio compare to its industry?

Colinz Laboratories Ltd has a P/E ratio of 11.8, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Colinz Laboratories Ltd financially healthy?

Key indicators for Colinz Laboratories Ltd: ROCE of 6.72 % is on the lower side compared to the industry average of 16.35%; ROE of 5.43 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Colinz Laboratories Ltd profitable and how is the profit trend?

Colinz Laboratories Ltd reported a net profit of ₹1 Cr in Mar 2025 on revenue of ₹7 Cr. Compared to ₹0 Cr in Mar 2022, the net profit shows an improving trend.

Does Colinz Laboratories Ltd pay dividends?

Colinz Laboratories Ltd has a dividend yield of 0.00 % at the current price of ₹46.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Colinz Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports